Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 2c, Offers FY19 and FY20 Guidance
Tweet Send to a Friend
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.13, $0.02 better than the analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
